Market Newsdesk

CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors.

“Chuck is a recognized biopharma leader who has made significant contributions in the advancement of precision oncology,” said David Mack, Ph.D., President and Chief Executive Officer of PMV. “His strong track record of success in building innovative oncology portfolios, from development through commercial launch, will be an ideal complement to our Board as we navigate our lead candidate, PC14856, through the clinic. We are thrilled to welcome him to the Board and look forward to leveraging his deep expertise in precision therapeutics that target the genetic drivers of cancer as we advance our pipeline of tumor-agnostic p53 reactivators.”

Dr. Baum said, “PMV’s unmatched expertise in p53 biology and innovative approach to precision oncology has the potential, for the first time, to address the most commonly mutated gene in cancer. I am enthusiastic about the Company’s platform of small molecules that restore the wild-type function of mutated p53 for targeted, and tumor agnostic, therapies. I am excited to join the Board of PMV and look forward to providing my guidance as the Company continues their execution, both in the clinic and across their development pipeline.”

Dr. Baum has served as the President and Chief Executive Officer and as a Board Member of Mirati Therapeutics Inc. since 2012. Under his leadership, Mirati has transformed into a precision oncology company focused on advancing its drug discovery and research and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.

Prior to joining Mirati, Dr. Baum was at Pfizer from 2003 to 2012, most recently as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division, and prior to that, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta,* Xalkori* and the approval of Sutent.* Prior to Pfizer, Dr. Baum was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.* Dr. Baum started his career with academic and clinical positions at Stanford and Emory Universities. He currently serves as Chairman of the Board at OncoMyx Therapeutics, Board of Directors member at BCTG Acquisition Corp and on the Scientific Advisory Board at ALX Oncology. He served as a member of the Board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer and Immunomedics from 2019 to 2020 when it was acquired by Gilead.

Dr. Baum received his M.D. (Medicine) and Ph.D. (Immunology) degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.

* Trademarks are property of their respective owners.

About p53

p53 plays a pivotal role in preventing abnormal cells from becoming a tumor by inducing programmed cell death. Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy. The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian cancers.

About PC14586

PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the crevice present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein structure and tumor suppressing function. PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for PC14586, including expectations regarding the success of its current clinical trial for PC14586; and the future plans or expectations for the Company’s discovery platform. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities and planned clinical trials, the Company’s ability to execute on its strategy and operate as an early clinical stage company, the potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2021, and its other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact

For Investors and Media:

Winston Kung
Chief Financial Officer
[email protected]

SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the fourth quarter and twelve months ended December 31, 2020.

Fourth Quarter Financial Highlights

• Total revenue in the fourth quarter was $4,608,000, a decrease of 3.7% when compared with the fourth quarter of 2019. Proton therapy revenue was $1,403,000, a decrease of 5.6% when compared with the fourth quarter of 2019. Gamma Knife revenue of $3,205,000 decreased 0.8% compared with the fourth quarter of 2019.

• Total proton therapy fractions decreased 25% compared to the fourth quarter of 2019. 
• Gamma Knife procedures increased by 3.1% to 427 for the fourth quarter of 2020 from 414 in the same period of the prior year. Gamma Knife volumes for centers in operation decreased 7.8% from Gamma Knife volumes for those same centers during the same period of the prior year.
• Operating loss for the fourth quarter of 2020 was $8,543,000 compared to operating income of $279,000 in the fourth quarter of 2019. Excluding a pre-tax write down of impaired assets in the fourth quarter of 2020 that totaled $8,264,000, operating loss was $279,000 which was primarily due to the lagging effects of COVID-19.
• Net loss in the fourth quarter was $6,231,000 compared to net income of $193,000 for the fourth quarter of 2019. The decrease in net income was primarily due to a pre-tax write down of impaired assets of $8,264,000 in the current period, which was substantially a non-cash charge.  

Ray Stachowiak, Chief Executive Officer of AMS, commented, “Since I was appointed CEO in September, my goal has been to provide AMS with a path to increased growth and sustained profitability. I believe that the action we have announced positions AMS to meet those goals and results in a significantly stronger balance sheet for the Company. This action is part of our strategic plan that also includes the diversification of our product offerings, geographic expansion and offering additional types of financing solutions to increase the Company’s revenue streams.”

“Operationally, we believe that our volumes were impacted by the spikes in COVID-19 illnesses during the fourth quarter and the resulting effect of outpatients continuing to delay their health care. This lag can be seen in our fourth quarter revenue, which is also a historically softer period for AMS. Revenue in the fourth quarter decreased 3.7% period-over-period. An increase in average reimbursement at our Proton Beam Radiation Center and the contribution from our acquisition of Gamma Knife Center Ecuador (“GKCE”) last June masked the period-over-period COVID-related volume declines in both PBRT and Gamma Knife operations. EBITDA was $2.5 million for the fourth quarter and we ended the year with a strong cash position of $4.3 million. Looking ahead, we expect reduced administrative expenses in the 2021 year, as we’ve previously discussed, and we’re excited to continue to execute on our strategy for growth from the stronger foundation that we built this quarter,” concluded Mr. Stachowiak.

Financial Results for the Three Months Ended December 31, 2020

For the three months ended December 31, 2020, total revenue was $4,608,000, a decrease of 3.7% when compared with $4,786,000 reported for the fourth quarter of 2019.

Fourth quarter revenue for the Company’s proton therapy system installed at Orlando Health in Florida was $1,403,000, a decrease of 5.6% when compared with the fourth quarter of 2019. Average reimbursement increased period-over-period which offset a decrease in volumes. Total proton therapy fractions decreased 25% compared to the fourth quarter of 2019. The period-over-period decrease was due to the impact from the spike of COVID-19 illnesses in the fourth quarter compounded by maintenance-related downtime.

Revenue for the Company’s Gamma Knife operations was $3,205,000, a 0.8% decrease compared with the fourth quarter of 2019. The slight period-over-period decline was due to lower volumes at same stores, offset by the acquisition of GKCE. Gamma Knife procedures increased by 3.1% to 427 for the fourth quarter of 2020 from 414 in the same period of the prior year. The increase reflects the acquisition of GKCE. Gamma Knife volumes for centers in operation decreased 7.8% from Gamma Knife volumes for those same centers during the same period of the prior year.

Gross margin for the fourth quarter of 2020 decreased to $1,027,000, or 22.3% of revenue, compared to gross margin of $1,441,000, or 30.1% of revenue, for the fourth quarter of 2019, primarily due to the lingering effects of COVID-19.

Selling and administrative costs increased by $193,000, or 22.5%, to $1,052,000 for the fourth quarter compared to $859,000 for the fourth quarter of 2019. The period-over-period increase is due to increases in tax and audit expenses, primarily attributable to the GKCE Acquisition, stock-based compensation, and software related expenses.

Operating loss for the fourth quarter of 2020 was $8,543,000 compared to operating income of $279,000 in the fourth quarter of 2019. Excluding a pre-tax write down of impaired assets in the fourth quarter of 2020 that totaled $8,264,000, operating loss was $279,000 which was primarily due to the lagging effects of COVID-19.  The write down of impaired assets includes the Company’s deposits for two PBRT units, six Gamma Knife units and associated removal costs.

Net loss for the fourth quarter of 2020 was $6,231,000, or $(1.01) per share, which includes a pre-tax write down of impaired assets of $8,264,000.  This compares to net income for the fourth quarter of 2019 of $193,000, or $0.03 per diluted share. Fully diluted weighted average common shares outstanding were 6,154,000 and 5,889,000 for the fourth quarter of 2020 and 2019, respectively.

Adjusted EBITDA, a non-GAAP financial measure, was $2,538,000 for the fourth quarter of 2020, compared to $2,056,000 for the fourth quarter of 2019. The year-over-year increase was primarily due to the effect of non-controlling interests on the impairment charge.

Financial Results for the Twelve Months Ended December 31, 2020

For the twelve months ended December 31, 2020, revenue decreased 13.4% to $17,837,000 compared to revenue of $20,605,000 for the twelve months of 2019. The decrease was primarily due to a decrease in average reimbursement for Gamma Knife procedures and a decrease in PBRT fractions, which are largely attributable to the COVID-19 pandemic. The Company recorded no revenue from its IGRT equipment in the twelve-month 2020 period compared to $840,000 in the comparable period of 2019, after the expiration of the Company’s contract and the equipment was fully depreciated and sold.

Proton therapy revenue decreased 0.8% to $6,167,000 for the twelve months of 2020 compared to $6,214,000 for the twelve months of 2019. Total proton therapy fractions for the 2020 year were 5,868, a decrease of 2.5%, compared to 6,018 proton therapy fractions for 2019. PBRT revenue declined due to the impact on volumes in the second and fourth quarters from the COVID-19 pandemic.

Gamma Knife revenue decreased 13.9% to $11,670,000 for the twelve months of 2020 compared to $13,551,000 for the twelve months of 2019. The year-over-year revenue decline was due to a lower average reimbursement at the Company’s retail sites. The number of Gamma Knife procedures in the twelve months of 2020 was 1,530, an increase of 2.1% compared to 1,498 Gamma Knife procedures in the comparable period of 2019. The increase was due to the Company’s acquisition of GKCE that was completed in June 2020. The increase was offset by a Gamma Knife contract that terminated in October 2020 as well as the impact of the COVID-19 pandemic.  

Operating loss for 2020 was $9,463,000 compared to operating income of $1,542,000 for 2019. Excluding a pre-tax write down of impaired assets in the fourth quarter of 2020 that totaled $8,264,000, operating loss was $1,199,000 for 2020. The write down of impaired assets includes the Company’s deposits for two PBRT units, six Gamma Knife units and associated removal costs.

Net loss for the twelve months of 2020 was $7,058,000, or $(1.14) per share which includes a pre-tax write down of impaired assets of $8,264,000.  This compares to net income for the twelve months of 2019 of $659,000, or $0.11 per diluted share. Fully diluted weighted average common shares outstanding were 6,182,000 and 5,930,000 for 2020 and 2019, respectively.

Adjusted EBITDA, a non-GAAP financial measure, was $7,776,000 for 2020, compared to $9,676,000 for 2019.

Balance Sheet Highlights

At December 31, 2020, cash, cash equivalents, and restricted cash was $4,325,000 compared to $1,779,000 at December 31, 2019.  Shareholders’ equity at December 31, 2020 was $23,650,000, or $4.08 per outstanding share.  This compares to shareholders’ equity at December 31, 2019 of $31,811,000, or $5.47 per outstanding share.

Conference Call and Webcast Information

AMS has scheduled a conference call at 10:00 a.m. PST (1:00 p.m. EST) today. To participate, please call 1 (877) 317-6789 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call. A simultaneous Webcast of the call may be accessed through the Company’s website, www.ashs.com, or at www.streetevents.com for institutional investors.

A replay of the call will be available at 1 (877) 344-7529, access code 10153925, through April 13, 2021.

About American Shared Hospital Services (NYSE American: AMS)

American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems. For more information, please visit: www.ashs.com.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and MR/LINAC businesses, the risks of the COVID-19 pandemic and its effect on the Company’s business operations and financial condition, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the three months ended March 31, 2020, June 30, 2020, and September 30, 2020 and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 26, 2020.

Non-GAAP Financial Measure

Adjusted EBITDA, the non-GAAP measure presented in this press release and supplementary information, is not a measure of performance under the accounting principles generally accepted in the United States (“GAAP”).  This non-GAAP financial measure has limitations as an analytical tool, including that it does not have a standardized meaning. When assessing our operating performance, this non-GAAP financial measure should not be considered a substitute for, and investors should also consider, income (loss) before income taxes, income (loss) from operations, net income (loss) attributable to the Company, earnings (loss) per share and other measures of performance as defined by GAAP as indicators of the Company’s performance or profitability.

Adjusted EBITDA is a non-GAAP financial measure representing our (loss) earnings before interest, taxes, depreciation, and amortization. We define Adjusted EBITDA as net (loss) income before interest expense, income tax (benefit) expense, depreciation and amortization expense, stock-based compensation expense, write down of impaired assets, associated removal costs, and acquisition transaction costs.

We use this non-GAAP financial measure as a means to evaluate period-to-period comparisons. Our management believes that this non-GAAP financial measure provides meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as stock-based compensation expense.  We believe that both management and investors benefit from referring to this non-GAAP financial measure in assessing our performance.

Contacts:

American Shared Hospital Services
Ray Stachowiak
Chief Executive Officer
[email protected]

Investor Relations
PCG Advisory
Stephanie Prince
P: (646) 863-6341
[email protected]

American Shared Hospital Services
Statement of Operations
		Summary of Operations Data
		Three months ended December 31,				Twelve months ended December 31,
		2020		2019		2020		2019
Revenues		$4,608,000		$4,786,000		$17,837,000		$20,605,000
		4,608,000		4,786,000		17,837,000		20,605,000
Costs of revenue		3,581,000		3,345,000		13,371,000		13,685,000
Gross margin		1,027,000		1,441,000		4,466,000		6,920,000
Loss on write down of impaired assets and associated removal costs		8,264,000		0		8,264,000		0
Selling & administrative expense		1,052,000		859,000		4,608,000		4,060,000
Interest expense		254,000		303,000		1,057,000		1,318,000
Operating (loss) income		(8,543,000)		279,000		(9,463,000)		1,542,000
Other income		3,000		1,000		10,000		16,000
(Loss) income before income taxes		(8,540,000)		280,000		(9,453,000)		1,558,000
Income tax (benefit) expense		(1,545,000)		(122,000)		(1,737,000)		128,000
Net (loss) income		(6,995,000)		402,000		(7,716,000)		1,430,000
Less: Net loss (income) attributable to non-controlling interest		764,000		(209,000)		658,000		(771,000)
Net (loss) income attributable to American Shared Hospital Services		(6,231,000)		193,000		(7,058,000)		659,000
(Loss) earnings per common share:
Basic		$             (1.01)		$               0.03		$             (1.14)		$               0.11
Assuming dilution		$             (1.01)		$               0.03		$             (1.14)		$               0.11
American Shared Hospital Services
Balance Sheet Data
		Balance Sheet Data
		12/31/2020		12/31/2019
Cash, cash equivalents and restricted cash		$4,325,000		$1,779,000
Current assets		$10,850,000		$10,742,000
Total assets		$43,653,000		$53,783,000
Current liabilities		$12,380,000		$8,214,000
Shareholders’ equity		$23,650,000		$31,811,000

	American Shared Hospital Services
	Adjusted EBITDA
	(Reconciliation of GAAP to Non-GAAP Adjusted Results)
		Q4	Q4		YTD	YTD
		2020	2019		2020	2019
Net (loss) income		$  (6,231,000)	$      193,000		$  (7,058,000)	$      659,000
Plus:	Income tax (benefit) expense	(1,545,000)	(122,000)		(1,737,000)	128,000
	Interest expense	254,000	303,000		1,057,000	1,318,000
	Depreciation and amortization expense	1,686,000	1,622,000		6,789,000	7,341,000
	Stock-based compensation expense	110,000	60,000		299,000	230,000
	Acquisition transaction costs	–	–		162,000	–
	Loss on write down of impaired assets and associated removal costs	8,264,000	–		8,264,000	–
Adjusted EBITDA		$    2,538,000	$    2,056,000		$    7,776,000	$    9,676,000

ZUG, Switzerland and CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 9:30 a.m. ET.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following each presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:

Susan Kim
+1-617-307-7503
[email protected]

Media Contact:

Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
[email protected]

WEST PALM BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) — AFC Gamma, Inc. (NASDAQ:AFCG) (“AFC”) today announced it has provided a credit facility of up to $21 million for FarmaceuticalRX LLC (“FarmRX”, the “Company”, or the “Borrower”). The credit facility is designed to provide capital to allow FarmRX to purchase and complete the build out of its +/-120,000 square foot Class 1 cultivation and processing facility and acquire the building housing its nearby dispensary operations in East Liverpool, Ohio.

“We are excited to support FarmaceuticalRX, an experienced operator in Pennsylvania as it expands into Ohio, a state that has favorable supply and demand dynamics and significant growth prospects,” said Leonard M. Tannenbaum, AFC’s Chief Executive Officer. “We believe this partnership will serve as the catalyst for FarmRX’s next phase of growth.”

Rebecca Meyers, FarmRX’s Chief Executive Officer, added, “I am thrilled to partner with AFC Gamma as we build out FarmRX’s presence in Ohio. AFC provided us with industry expertise and a tailored solution that met our needs, providing seamless execution in a timely manner.”

AFC will hold up to $21 million of the credit facility, which consists of a first-lien term loan that can be drawn upon over the course of a one-year period. The loan will be secured by first-lien mortgages on FarmRX’s wholly owned real estate properties and other commercial-security interests. AFC Management, LLC served as Lead Arranger and Administrative Agent for the transaction.

Based in East Liverpool, Ohio, FarmRX currently has one dispensary license, one provisional Class 1 cultivation license, and one provisional processing license in the state. FarmRX’s dispensary is currently operational and it is in the process of building out its cultivation and processing operations, with a sister company having existing cultivation operations in Pennsylvania.

Ohio legalized the use of medical marijuana in 2016, with sales launching in 2019.   In 2021, sales from dispensaries are projected to reach $425 million, nearly doubling 2020 sales of $221.5 million¹. Sales are expected to top $500 million by 2022 or 2023. As of March 19, 2021, the number of registered patients in the state was over 175,000.

About AFC Gamma, Inc.

AFC Gamma, Inc. (NASDAQ:AFCG) is an institutional lender to leading cannabis companies with strong operations and cash-flow prospects, real-estate-security and other collateral, and locations in states with favorable supply/demand fundamentals and legislative environments. AFC’s platform provides innovative and customized financing solutions through first-lien loans, mortgage loans, construction loans and bridge financings. The senior-management team of the company has a combined approximately 100 years of experience in investment management and disciplined credit investing across a range of economic cycles.

About FarmaceuticalRX

FarmaceuticalRX LLC is the leading natural and organic multistate vertically integrated medical marijuana operator in the United States. FarmaceuticalRX is focused on bringing research and development-based innovation to the medical marijuana sector. develops premier high-quality craft and innovative organic products under its existing FarmaceuticalRX brand. The Company’s Burst of Wellness brand combines the quality that FARMACEUTICALRX is known for, at a lower price point, with the goal of expanding the Company’s reach to a broader demographic of patients. The FarmaceuticalRX affiliated companies are licensed to offer premier high quality medical marijuana products to more than 26 million patients in Ohio and Pennsylvania. FarmaceuticalRX is led by a world-class team of scientists, healthcare, organic food and beverage and cannabis industry professionals who are driven by the discovery, development, and manufacturing of revolutionary, high quality natural and organic products through its vertically integrated platform. Our innovation is your future health. Learn more at www.farmaceuticalrx.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the company’s current views and projections with respect to, among other things, future events and financial performance.  All statements other than historical facts, including, without limitation, statements regarding FarmRX’s intended buildout and the projected sales of medical marijuana in Ohio are forward-looking statements. Words such as “believes,” “expects,” “will,” “intends,” “plans,” “guidance,” “estimates,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements.  These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and are not guarantees of future performance, conditions or results.  Certain factors, including the borrower failing to complete the construction described above, an unfavorable change in the regulations of the cannabis industry and other important risks and uncertainties discussed under the caption “Risk Factors” in our final prospectus filed with the U.S. Securities Exchange Commission on March 19, 2021, relating to the company’s Registration Statement on Form S-11, as amended (File No. 333-251762), could cause actual results and performance to differ materially from those projected in these forward-looking statements.  New risks and uncertainties arise over time, and it is not possible for the company to predict those events or how they may affect AFC Gamma, Inc. Therefore, you should not place undue reliance on these forward-looking statements.  The company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AFC GAMMA INVESTOR CONTACT:

Robyn Tannenbaum
561-510-2293
[email protected]
www.afcgamma.com

AFC GAMMA MEDIA CONTACT:

Jim Golden / Scott Bisang / Jack Kelleher
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

COMPANY CONTACT:

Terence Lin
Director of Strategic Finance, FarmaceuticalRX
[email protected]

¹ Ohio’s growing medical marijuana market poised to reach $400 million in sales a year (Marijuana Business Daily, March 29, 2021)

LOS ANGELES, April 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Tony DiMatteo, CEO and co-founder of Lottery.com, a next generation platform where consumers can play the lottery online, recently appeared on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff.

To hear the full podcast, visit: The Dealmaker Show

Lottery.com recently entered into a definitive agreement to become a public company through a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC). Once the transaction is complete, the combined company will be trademarked as Lottery.com, with its common stock to remain listed on Nasdaq under ticker symbol “LTRY”.

Klaff kicked off the interview by diving headfirst into Lottery.com’s operations, asking DiMatteo how Lottery.com’s business compares with similar companies in their space.

“I see us as sort of an entertainment company or a media company, really. We let people play the games that they already like right now, and they can do that from their phones,” DiMatteo stated. “All we’re doing is taking something that’s a legacy industry which is paper based… and making that available to everybody, through their phones or online.”

“When we started… it was incredibly hard in so many different ways… One challenge was ‘How do we do this? What’s a legal way to play the lottery online?’ That was a huge hill to climb,” DiMatteo added. “When I met Matt [Clemenson], my co-founder, our thesis was to build things that should exist or are inevitable to exist… We built some very cool tech in totally unrelated spaces, and we got some patents on that and it was awesome. But once we found the lottery, it was like ‘this is the biggest pie that we can imagine’ and we had an opportunity… We’re the right combination of smart, stupid and stubborn to go and do this. Everybody told us originally that there’s no way you can do this, nobody is going to allow you to do this, no state is going to allow you to operate, but we were smart enough to understand the world and see what’s possible, dumb enough to just ignore everybody who told us ‘no’ and stubborn… we said, ‘we’re going to make this happen’.”

“We started about six years ago. It took us five years to get a few states open, basically meaning that you can actually play the lottery from your phone,” he continued. “In the last year, we’ve opened up seven [additional] states… Once the [COVID-19] quarantine happened, people could not walk in with paper money and walk out with a paper ticket. The states realized ‘we cannot continue business as usual; we have to go online, we have to modernize’… [Lottery.com] is in 12 states now; we are looking to open up more this year. Also, we’re very aggressive on international expansion… Our long-term vision is to become a global marketplace for games of chance.”

Throughout the interview, DiMatteo provided an extensive overview of the story behind Lottery.com’s founding, reflected on stories of past lottery winners and highlighted the company’s charitable efforts through its WinTogether.org initiative.

About Lottery.com

Lottery.com is an Austin, Texas-based company enabling consumers to play state-sanctioned lottery games from their home or on the go in the U.S. and internationally. The company works closely with state regulators to advance the lottery industry, providing increased revenues and better regulatory capabilities, while capturing untapped market share, including millennial players. Lottery.com is also gamifying charitable giving to fundamentally change how nonprofits engage with their donors and raise funds. Through its WinTogether.org platform, Lottery.com offers charitable donation sweepstakes to incentivize donors to take action by offering once in a lifetime experiences and large cash prizes. For more information, visit the company’s website at www.lottery.com

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this presentation, regarding the proposed business combination between Trident and Lottery.com, Trident and Lottery.com’s ability to consummate the transactions, the benefits of the transactions, Lottery.com’s estimated growth, operational and state expansion, and the combined company’s future financial performance, as well as the combined company’s strategy, future operations, estimated financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Lottery.com disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Lottery.com cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of either Trident or Lottery.com. In addition, Lottery.com cautions you that the forward-looking statements contained in this press release are subject to the following factors: (i) the occurrence of any event, change or other circumstances that could delay the business combination or give rise to the termination of the agreements related thereto; (ii) the outcome of any legal proceedings that may be instituted against Trident or Lottery.com following announcement of the proposed business combination; (iii) the inability to complete the business combination due to the failure to obtain approval of the stockholders of Trident, or other conditions to closing in the business combination agreement; (iv) the risk that the proposed business combination disrupts Lottery.com’s current plans and operations as a result of the announcement of the transactions; (v) Lottery.com’s ability to realize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of Lottery.com to grow and manage growth profitably following the business combination; (vi) costs related to the business combination; (vii) risks related to the rollout of Lottery.com’s business and the timing of expected business milestones; (viii) Lottery.com’s dependence on obtaining and maintaining lottery retail licenses or consummating partnership agreements in various markets; (ix) Lottery.com’s ability to maintain effective internal controls over financial reporting, including the remediation of identified material weaknesses in internal control over financial reporting relating to segregation of duties with respect to, and access controls to, its financial record keeping system, and Lottery.com’s accounting staffing levels; (x) the effects of competition on Lottery.com’s future business; (xi) risks related to Lottery.com’s dependence on its intellectual property and the risk that Lottery.com’s technology could have undetected defects or errors; (xii) changes in applicable laws or regulations; (xiii) the COVID-19 pandemic and its effect on Lottery.com and the economy generally; (xiv) risks related to disruption of management time from ongoing business operations due to the proposed business combination; (xv) risks relating to privacy and data protection laws, privacy or data breaches, or the loss of data; and (xvi) the possibility that Lottery.com may be adversely affected by other economic, business, and/or competitive factors. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Trident has filed and will file from time to time with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Trident’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

Participants in the Solicitation

Trident and its directors and officers may be deemed participants in the solicitation of proxies of Trident’s shareholders in connection with the proposed business combination. Lottery.com and its officers and directors may also be deemed participants in such solicitation. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Trident’s executive officers and directors in the solicitation by reading Trident’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the Proxy Statement and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of Trident’s participants in the solicitation, which may, in some cases, be different than those of their stockholders generally, will be set forth in the proxy statement relating to the business combination when it becomes available.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

WASHINGTON, April 06, 2021 (GLOBE NEWSWIRE) — Today, the Cannabis Freedom Alliance (CFA) launched to end the prohibition, criminalization, and overregulation of cannabis in the United States. The CFA aims to do so in a manner consistent with helping all Americans achieve their full potential and limiting the number of barriers that inhibit innovation and entrepreneurship in a free and open market.

Steering Membership includes prominent national advocacy organizations Americans for Prosperity (AFP), Mission Green/The Weldon Project, the Reason Foundation, and the Global Alliance for Cannabis Commerce (GACC). Weldon Anglos of Mission Green/The Weldon Project and Randal John Meyer of GACC serve as co-Coordinators for the Coalition.

Weldon Angelos stated, “Ending cannabis prohibition and incarceration is a moral imperative. For too long, cruel laws punishing non-violent cannabis offenses have destroyed the lives of individuals throughout this country—myself included. It is high time that Congress and the President right this wrong and allow those harmed by cannabis prohibition the chance to participate in the cannabis industry like the millionaires and billionaires doing so now. But we can’t do this alone. We need both sides to come together on this, which is why we launched this coalition.”

The CFA is aimed at accomplishing four core values through federal legislative reform:

• Federal De-Scheduling and Criminal Justice Reform. Seek the complete removal of cannabis from the Schedules of the Controlled Substances Act to bring an end to cannabis criminalization, and allow innovation, industry, and research to thrive.
• Reentry and Successful Second Chances. Seek to ensure individuals who were formerly incarcerated or current grey-market operators are given a second chance in society and have an equal ability to contribute to the cannabis market during its transition from an illicit to legal market.
• Promoting Entrepreneurship in Free and Open Markets. Seek federal and state regulatory frameworks for cannabis which promote public safety while ensuring low barriers to entry and non-restrictive occupational and business licensing is the norm. Market rules must not allow control by crony interests or inhibit small companies and entrepreneurs through unnecessary limitations or overregulation.
• Competitive and Reasonable Tax Rates. Seek to ensure the total tax burden – federal, state, and local combined – imposed on cannabis businesses should not raise costs so as to incentivize the continuation of illicit markets.

“For too long, the criminalization of cannabis has hurt Americans, from individuals’ unnecessary involvement with the justice system to the damage dealt to communities by the expensive and failed ‘War on Drugs,’” said Brent W. Gardner, Chief Government Affairs Officer for Americans for Prosperity. “Americans for Prosperity is excited to work alongside our partners to bring cannabis businesses into the light, replacing black and gray markets with a free and fair legal framework that improves public safety and emphasizes entrepreneurship and equal opportunity. In this context, cannabis commerce will become a way for Americans to lift themselves up, rather than a barrier holding them back.”

Reason Foundation Vice President of Policy Dr. Adrian Moore noted, “We are excited to work together on the twin goals of ending the failed prohibition of cannabis, with all the costs to lives, liberty and the economy that come with it, and ensuring that cannabis black markets are replaced with free, fair and competitive legal cannabis markets.”

GACC Board Chairman Rezwan Khan added, “GACC is excited to join together to help bring about the end of cannabis prohibition. We look forward to ensuring a vibrant and competitive legal cannabis industry that restores the harms of those adversely impacted by prohibition.”

For more information on the CFA or to join our efforts, please visit our website at cannabisfreedomalliance.org or email us at [email protected].

About the Cannabis Freedom Alliance:

The

Cannabis Freedom Alliance

(CFA) is a coalition of advocacy and business organizations seeking to end the prohibition and criminalization of cannabis in the United States in a manner consistent with helping all Americans achieve their full potential and limiting the number of barriers that inhibit innovation and entrepreneurship in a free and open market. For more information on the CFA, please contact [email protected].

About the Americans for Prosperity:

Through broad-based grassroots outreach, Americans for Prosperity (AFP) is driving long-term solutions to the country’s biggest problems. AFP activists engage friends and neighbors on key issues and encourage them to take an active role in building a culture of mutual benefit, where people succeed by helping one another. AFP recruits and unites activists in 35 states behind a common goal of advancing policies that will help people improve their lives. For more information, please visit


www.AmericansForProsperity.org


.

About The Weldon Project/Mission Green:



Mission Green


is an initiative of The Weldon Project that brings together individuals impacted by the criminal justice system and unlikely allies from all sides of the political spectrum to push for criminal justice solutions. The organization works directly with lawmakers, celebrities, advocacy groups, incarcerated individuals, and the White House on a broad range of criminal justice issues. Notably, TWP helped pass the historic, bipartisan criminal justice reform legislation called the First Step Act which was signed into law in December 2018. TWP launched the Mission Green initiative to focus exclusively on individuals incarcerated for cannabis-related offenses in the criminal justice system. The Mission Green campaign is led by people who have been directly impacted by prohibition and have lived through the issues that advocacy organizations are working to address. The people most affected by the current justice system are in a unique position to bring about transformative change. For more information, please contact Weldon Angelos at
[email protected].

About the Reason Foundation:



Reason Foundation


is a nonprofit think tank dedicated to advancing free minds and free markets. Reason Foundation produces respected public policy research on a variety of issues and publishes the critically acclaimed


Reason magazine and its website


. For more information, please contact Dr. Adrian Moore at [email protected].

About the Global Alliance for Cannabis Commerce:

The

Global Alliance for Cannabis Commerce

(GACC) exists to provide policymakers and legislators with the guidance necessary to take the nascent cannabis industry from the grey market into a global provider of medical and adult-use cannabis products. GACC advocates in front of government policymakers and legislators in order to legalize and regulate the cultivation, manufacture, distribution, or use of medical and adult-use cannabis products globally. For more information, please contact Randal John Meyer at [email protected].

CON
TACT

Weldon Angelos

[email protected]

Randal John Meyer

rand
[email protected]

YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM

Shared therapeutic target with Parkinson’s disease expands potential utility of 

YTX-7739 to non-neurodegenerative diseases

Study presented at
SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study that demonstrate in vivo efficacy, including increased median overall survival, of YTX-7739 in a mouse model for glioblastoma multiforme (GBM). The study was conducted by researchers at the Massachusetts General Hospital and is being presented virtually today at the Society for NeuroOncology/National Cancer Institute (SNO/NCI) Joint Symposium: Targeting CNS Tumor Metabolism. YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinson’s disease.

The research entitled, Targeting Fatty Acid Biosynthesis in Glioblastoma, was conducted in the laboratory of Christian E. Badr, Ph.D., of Massachusetts General Hospital and presented by Katharina M. Eyme. They had recently shown that GBM cancer stem cells are highly susceptible to pharmacological permutation of stearoyl-CoA desaturase (SCD). SCD inhibition in these cells leads to the toxic accumulation of saturated fatty acids and impairs DNA damage repair, hence sensitizing cells to DNA-damaging agents such as temozolomide (TMZ). In this study, YTX-7739, an orally available SCD inhibitor that is in clinical development for the treatment of Parkinson’s disease, was administered either alone or with TMZ to mice following intracranial implantation of GBM cells. The investigators found that YTX-7739, and a second SCD inhibitor in development by Yumanity, YTX-9184, each increased median survival as monotherapy and was synergistic with TMZ in both aggressive and slow growing tumors. The authors concluded that SCD inhibition could possibly be a viable approach to improving treatment of GBM in humans, as either single or adjunctive therapy.

“These data point to modulation of SCD activity as a potential shared therapeutic target between Parkinson’s disease and glioblastoma, expanding the potential promise of our lead asset, YTX-7739, to non-neurodegenerative brain diseases,” said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. “As a science-driven organization that is dedicated to developing disease-modifying drugs for patients with high unmet medical needs, we are working with our collaborators at the Massachusetts General Hospital to explore its compelling preclinical results and how they might be leveraged to benefit patients suffering from glioblastoma.”

About YTX-7739

YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD). SCD appears to play an important and previously unrecognized role in mitigating neurotoxicity arising from the effects of pathogenic alpha-synuclein protein aggregation and accumulation, which ultimately results in the death of neurons and the subsequent dysregulation of movement and cognition that afflicts patients living with these diseases. Through inhibition of SCD, YTX-7739 modulates an upstream process in the alpha-synuclein pathological cascade and has been shown to rescue or prevent toxicity in cellular and preclinical models. The company is assessing the potential utility of YTX-7739 as a disease modifying therapy for Parkinson’s disease.

About SCD

SCD is an enzyme that catalyzes fatty acid desaturation, the products of which are incorporated into phospholipids, triglycerides, or cholesterol esters. These lipid-related molecules regulate multiple diverse cellular properties and processes, including membrane structure and function, vesicle trafficking, intracellular signaling and inflammation. SCD expression is regulated by a transcription factor known as SREBF1, which has been identified in human genome-wide association studies as a risk factor for Parkinson’s disease. In preclinical models, SCD inhibition appears to normalize the dynamic interaction of pathological alpha-synuclein with membranes, which improves neuronal function and reduces toxicity, leading to enhanced neuronal survival. Alpha-synuclein-dependent disruption of membrane-related biological pathways, such as vesicle trafficking, is closely linked to the formation of Lewy body protein/membrane aggregations, a hallmark pathological feature of Parkinson’s disease.

About Yumanity Therapeutics

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the potential therapeutic benefits of our prospective product candidates and results of preclinical studies, including YTX-7739, and the design, commencement, enrollment, and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, and the anticipated benefits of our drug discovery platform. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on Yumanity Therapeutics’ current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of Yumanity Therapeutics or our collaborators, the risk that Yumanity Therapeutics may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that Yumanity Therapeutics may not realize the intended benefits of its drug discovery platform, the risk that our product candidates will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving Yumanity Therapeutics’ product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Yumanity Therapeutics’ actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the definitive proxy statement/prospectus/information statement filed with the Securities and Exchange Commission on November 12, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Yumanity Therapeutics’ subsequent filings with the Securities and Exchange Commission. Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investors:

Burns McClellan, Inc.
John Grimaldi
[email protected]
(212) 213-0006

Media:

Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
[email protected] / [email protected]
(212) 213-0006

BELLEVUE, Wash., April 06, 2021 (GLOBE NEWSWIRE) — EagleView, a leading geospatial technology provider of software, aerial imagery and analytics, today announced the appointment of Tad Finer as Chief Revenue Officer. At EagleView, Finer will report to CEO Chris Jurasek, and will lead the organization’s entire revenue generation organization.

“I am thrilled to welcome Tad and his vast wealth of experience transforming the sales processes of technology leaders on board at EagleView,” said Jurasek, CEO of EagleView. “As EagleView enters its next phase of growth, Tad’s industry knowledge and business acumen will serve the company well.”

Tad joins EagleView from Workiva (NYSE: WK), where he was Senior Vice President of Global Sales. Previously, he was the General Manager of Workiva’s Integrated Risk division, as well as the Vice President of Global Partnerships and Alliances. Throughout his 20-year career in technology, Tad has served in a variety of sales leadership roles at IBM, Software AG and HyperGrid (now CloudSphere). Tad holds a BA from the University of Idaho and an MBA from George Washington University.

“As a leader in geospatial technology, EagleView has an incredible opportunity to drive innovation for our existing customer base and in additional industries,” said Finer, CRO of EagleView. “I am excited to join the organization and develop new ways to better serve the industries we help transform on a daily basis.”

About EagleView

EagleView is a leader in geospatial technology, providing software, imagery and analytics that transform the way our customers work. EagleView has the largest geospatial data and imagery library in history, covering 94 percent of the U.S. population. EagleView’s unique technology with over 300 patents creates highly differentiated software, imagery and analytics products for a diverse customer base.

For more information, call (866) 659-8439, visit www.EagleView.com and follow @EagleViewTech.

Nick Fathergill
EagleView Technologies
[email protected]

ISLAND PARK, N.Y., April 06, 2021 (GLOBE NEWSWIRE) — Global Diversified Marketing Group Inc. (OTC: GDMK), a multi-line consumer packaged goods company, is pleased to debut the re-brand of our website properties at 360worldsnacks.com as a one stop snack pantry which will define us as a new exciting snack marketplace.  We eagerly invite all of our valued customers and shareholders to visit the new site and explore the innovative features and listings that have been added and will continue to be added throughout the year.

The new site will start off with our popular branded items and we’ll be adding other brands and high velocity products and snacks to this marketplace within the next 120 days. Our initial goal will be to reach 500 different SKUs carried on the platform to please the discerning tastes and preferences of as many different consumers as we possibly can.

To further enhance the value of GDMK product offerings we will provide 2-day free shipping all across the United States. For orders that reach $50 in the cart, we’ll also give the consumer an option to add any additional items/SKUs to the cart at a special promotion off the listed price. Why? Because we LOVE our customers and we want to make it easy and fun to have their favorite gourmet snacks ordered and delivered right to their snack pantries!

CEO Paul Adler commented, “With the rapidly growing popularity of the Global Diversified Marketing Group premium snack food lines we knew it was time to rebrand our website to make it a much more inviting and user-friendly experience for all visitors. Since we have so many different kinds of great customers, all with different preferences in the snack food world, we also decided to make a commitment to listing as many different high-quality gourmet items as possible so that everyone can find their favorite choices. Order fulfillment will be easier than ever with special discounts on products when you order more. Enjoy!

For more information on Global Diversified Marketing Group (GDMK) Please visit us at: www.360worldsnacks.com 

About Global Diversified Marketing Group

Headquartered in Island Park, NY – Global Diversified Marketing Group Inc operates as a global multi-line consumer packaged goods (“CPG”) company with branded product lines and is a food and snack manufacturer, importer and distributor in the United States, Canada, and Europe. The Company operates in the snacks market segment and offers Italian Wafers, Italian filled Croissants, French Madeleines, Wafer Pralines, shelf-stable Macarons, and other gourmet snacks. The company sells its products directly through various distribution channels comprising specialty, grocery retailers, food-service distributors, direct store delivery (“DSD”) as well as the vending, pantry, and the micro-market segment.

Safe Harbor Statement

Certain statements in this announcement are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include, but are not limited to, information concerning the ability of the Company to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors. Those assumptions and factors are based on information currently available to the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability of the Company to develop the Company’s brand and meet its growth objectives, the ability of the Company to complete acquisitions that are accretive to the Company’s revenue, the ability of the Company to obtain and/or maintain licenses to operate in the jurisdictions in which it operates or in which it expects or plans to operate. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking information contained in this release is made as of the date hereof and the Company assumes no obligation to update or revise any forward-looking statements or forward-looking information that are incorporated by reference herein, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

The foregoing statements expressly qualify any forward-looking information contained herein. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Contact:

Global Diversified Marketing Group Inc

Paul Adler, Chairman, President & CEO

800-550-5996

[email protected]

TORONTO, April 06, 2021 (GLOBE NEWSWIRE) — BlueCat, the Adaptive DNS^TM company, announced today that it will be hosting the first annual, industry-wide celebration called DDI Day on April 13th. DDI denotes a combination of the critical network services – DNS, DHCP, and IP Address Management – without which digital connectivity is impossible. DDI Day recognizes the heroic efforts of IT professionals who keep these services working, and consequently, our world moving. DDI Day celebrations will feature:

• A panel discussion by industry pioneers Paul Mockapetris, Ralph Droms, and Russ White. Attendance is free via this registration page.
• An open invitation for the public to recognize a DDI professional via social networks using the hashtags #DDIHero #DDIDay.
• An awards ceremony to recognize today’s most hardworking DDI professionals.

Most people don’t think very much about DDI. But they should, because it’s like oxygen to anything that occurs digitally. What even fewer people know is that a relatively small community of professionals around the world are skilled enough to understand and manage the technological complexity of DDI required by our cities, hospitals, schools, entertainment centers, and places of employment.

“Managing DDI can often feel like a thankless job,” says BlueCat VP of Marketing, Jim Williams. “Those who keep DDI working have had a massive positive impact on every aspect of our increasingly digital lives. The effort and rare skill required to do so cannot be understated.”

To reserve your spot at DDI Day 2021 festivities, visit here. Then, as you wait for the event on the day-of, make sure to recognize somebody you know who works with DNS, DHCP, and/or IP Address Management for all their hard work keeping our systems running.

About Paul Mockapetris

Paul Mockapetris is an Internet advocate and investor. At present, he is Chief Scientist at ThreatSTOP.

In the past he was Chairman and Chief Scientist at Nominum, Chairman of an ICANN Strategic Panel, CTO at Urban Media, Siara, Fiberlane, Software.com and Director of Engineering at @Home. He has been IETF chair, program manager at ARPA, and did 15 years of research at the University of Southern California’s Information Sciences Institute, and 10 years at UC Irvine with the DCS project.

He is best known as the creator of the Domain Name System (DNS), and wrote the first implementation of SMTP. He received his learner’s permits in Physics and Electrical Engineering from the Massachusetts Institute of Technology in 1971, and his Ph.D. in Information and Computer Science from the University of California, Irvine, in 1982. He is the recipient of the IEEE 2003 Internet award, the ACM 2005 Sigcomm award, and the 2019 ACM Software System Award. He is a Fellow of the ACM, IEEE and the US National Academy of Engineering.

About Ralph Droms

Ralph Droms, PhD, organized the Dynamic Host Configuration Working Group in the IETF with Phill Gross and the support of Vint Cerf/CNRI in 1989 and chaired the WG until 2009. Ralph is co-author of the original DHCP RFCs RFC 2131 and RFC 2132, published in 1997, along with many other DHCP specifications and “The DHCP Handbook”. He also served in the IETF as a member of the IAB and the IESG, as well as organizing the Extensions for Scalable DNS Service Discovery Working Group with Tim Chown.

In addition to his work in the IETF, Ralph has been a contributor to the ZigBee Alliance “ZigBee over IP” specification, editor for the IPv6 functions in the CableLabs DOCSIS 3.0 specification and has contributed to other standards bodies. Ralph is currently with Google, and previously was on the research staff at Cisco, IBM and Burroughs. He has also held faculty positions at Bucknell and Penn State.

About Russ White

Russ White began working with computers in the mid-1980’s, and computer networks in 1990. He has experience in designing, deploying, breaking, and troubleshooting large scale networks, and is a strong communicator from the white board to the board room. He has co-authored more than forty software patents, participated in the development of several Internet standards, helped develop the CCDE and the CCAR, and worked in Internet governance with the Internet Society. Russ has a background covering a broad spectrum of topics, including radio frequency engineering and graphic design, and is an active student of philosophy and culture.

Russ is a co-host of the History of Networking and Hedge podcasts, serves on the Routing Area Directorate and the Internet Architecture Board at the IETF, co-chairs the BABEL working group, and serves on the Technical Services Council/as a maintainer on the open source FR Routing project. His most recent works are Computer Networking Problems and Solutions, Network Disaggregation Fundamentals video training, and Abstraction in Computer Networks video training.

About BlueCat

BlueCat is the Adaptive DNS™ company. The company’s mission is to help the world’s largest organizations thrive on network complexity, from the edge to the core. To do this, BlueCat re-imagined DNS. The result – Adaptive DNS™ – is a dynamic, open, secure, scalable, and automated resource that supports the most challenging digital transformation initiatives, like adoption of hybrid cloud and rapid application development. Learn more at www.bluecatnetworks.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01bb2164-26f0-471b-b078-eba8bc16e12a

Contact:
Dana Iskoldski
Corporate Communications Manager
[email protected]
647 222 1996